Project Grant R42DE028215

This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $1,722,291 to the University of Maryland, Baltimore to develop novel tunable metformin-releasing injectable scaffolds to enhance dental pulp stem cell-based craniofacial bone regeneration. The 5-year project, starting August 1, 2024, aims to test the hypothesis that transplantation of OCT1-expressing dental pulp...

This $1,488,960 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research Federal Grant Program (CFDA 93.121), supports research to understand the role of LGR+ connective tissue progenitor cells in the development of the temporomandibular joint (TMJ). The key objectives are to: 1) Perform lineage tracing to identify LGR4/LGR5 (mouse) and LGR4/LGR6 (zebrafish) as markers of connective tissue stem cells in the TMJ,...

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $388,575 Project Grant (CFDA 93.286: Discovery and Applied Research for Technological Innovations to Improve Human Health) to Rutgers, The State University in New Jersey. The project aims to develop a platform technology for encapsulating and delivering the bone morphogenic protein 2 (BMP-2) in hydrophobic polymer matrices. Using an active machine learning workflow, the project will optimize the formulation of...

Nostopharma LLC was awarded a $256,000 Small Business Technology Transfer Phase I Project Grant from the National Science Foundation to develop a sustained-release, biodegradable nanoparticle drug delivery system for treatment of soft tissue trauma complications. Funded under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the 12-month project beginning March 1, 2022 aims to demonstrate in vitro and in vivo feasibility of modulating the ectopic bone microenvironment...

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the federal grant program "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286), provides funding of $481,438 to the University of California, San Diego (UCSD) to develop a novel therapeutic delivery system called "Cargocytes." Cargocytes are derived from mesenchymal stem cells that have been genetically engineered to...

This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $306,868 to Cayman Chemical Co Inc. to develop novel small molecule pharmacotherapies that stimulate alveolar bone formation and regeneration. The project aims to create epigenetic inhibitors of the EZH2 enzyme, which can promote osteoblast activity and bone growth, for local delivery in dental applications....

This $271,664 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) aims to develop a novel biomaterial delivery platform to spatiotemporally deliver bone morphogenetic proteins (BMP2 and BMP9) to promote regeneration of bone and articular cartilage after digit amputation. Specifically, the project will engineer bioactive, magnetic...

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $752,620 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Washington University in St. Louis to develop injectable alginate hydrogels containing cell-adhesive peptides and insulin-like growth factor 1 (IGF-1) mimetic peptides. The goal is to enhance the therapeutic potential of mesenchymal stem cells (MSCs) for intervertebral disc (IVD) repair. The research will...

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), part of the Oral Diseases and Disorders Research Federal Grant Program (CFDA 93.121), provides $243,750 to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to explore the use of the FDA-approved iron oxide nanoparticle formulation ferumoxytol to activate orofacial mesenchymal stem/progenitor cells (OMSCs) and promote their...

This $672,394.58 project grant from the National Institutes of Health's National Institute of Dental and Craniofacial Research Oral Diseases and Disorders Research program (CFDA 93.121) supports the development of a crosslinkable tissue particle implant for regenerating craniofacial bone. Led by Leefa Biotech LLC, the one-year award aims to demonstrate improved bone regeneration in critical-size cranial bone defects using the implant compared to the current standard of care. If successful, the...